my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
17-03-2011: APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents. This transaction follows in the wake of successful in-licensing deals that Apeiron completed in the last six months.
Apeiron Biologics AG and Cleveland Clinic Foundation have entered into a set of agreements setting the framework for a collaboration on novel anti-cancer compounds currently in development at Cleveland Clinic. The collaboration includes an option to Apeiron to enter into a worldwide, exclusive license agreement with the Clinic relating to the compounds, and an Apeiron sponsored research agreement with the Clinic relating to these compounds and approach.
The compounds, tyrosine phosphatase inhibitors (TPI), have been designed to inhibit SHP-1, a protein tyrosine phosphatase, which is a key negative regulator of immune cell activation. Inhibition of SHP-1 leads to activation of the immune system to combat cancer.
No financial details are disclosed.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy
Evotec AG announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer. Apeiron Biologics will contribute in vitro and in vivo pharmacology expertise to this collaboration ... more
Apeiron Biologics AG announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients. Apeiron announced that a clinical trial has started with a liposomal topical ... more
Apeiron announced the initiation of a phase IIa clinical study of rhACE2, in patients with Acute Lung Injury (ALI). The study, of which Apeiron´s licensee GSK is sponsor, will include subjects with a positive diagnosis of ALI, and will be conducted in the intensive care units of multiple ho ... more
Apeiron Biologics is engaged in the focused development of innovative therapeutics based on validated targets derived from biomedical break-through discoveries. The company, operational since 2005, was founded by Josef Penninger, a top level scientist with high international reputation and ... more
APEIRON acquires option to license rights to oncology compounds from Cleveland Clinic
APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based ... more
Red wine compound increases anti-tumor effect of rapamycin
Researchers from Cleveland Clinic's Lerner Research Institute have discovered that resveratrol – a compound found in red wine – when combined with rapamycin can have a tumor-suppressing effect on breast cancer cells that are resistant to rapamycin alone. The research – recently published in ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
